Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)

Kayoko Yoshida, Chiyo Imamura, Kanako Hara, Mayumi Mochizuki, Yusuke Tanigawara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Everolimus selectively inhibits mammalian target of rapamycin complex 1 (mTORC1) and exerts an antineoplastic effect. Metabolic disturbance has emerged as a common and unique side effect of everolimus. Objectives: We used targeted metabolomic analysis to investigate the effects of everolimus on the intracellular glycometabolic pathway. Methods: Mouse skeletal muscle cells (C2C12) were exposed to everolimus for 48 h, and changes in intracellular metabolites were determined by capillary electrophoresis time-of-flight mass spectrometry. mRNA abundance, protein expression and activity were measured for enzymes involved in glycometabolism and related pathways. Results: Both extracellular and intracellular glucose levels increased with exposure to everolimus. Most intracellular glycometabolites were decreased by everolimus, including those involved in glycolysis and the pentose phosphate pathway, whereas no changes were observed in the tricarboxylic acid cycle. Everolimus suppressed mRNA expression of enzymes related to glycolysis, downstream of mTOR signaling enzymes and adenosine 5′-monophosphate protein kinases. The activity of key enzymes involved in glycolysis and the pentose phosphate pathway were decreased by everolimus. These results show that everolimus impairs glucose utilization in intracellular metabolism. Conclusions: The present metabolomic analysis indicates that everolimus impairs glucose metabolism in muscle cells by lowering the activities of glycolysis and the pentose phosphate pathway.

Original languageEnglish
Article number98
JournalMetabolomics
Volume13
Issue number8
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

Metabolic Networks and Pathways
Muscle Cells
Muscle
Skeletal Muscle
Cells
Glucose
Glycolysis
Pentoses
Pentose Phosphate Pathway
Metabolomics
Phosphates
Enzymes
Metabolism
Everolimus
Capillary electrophoresis
Messenger RNA
Citric Acid Cycle
Capillary Electrophoresis
Adenosine Monophosphate
Metabolites

Keywords

  • CE-TOFMS
  • Everolimus
  • Glycometabolism
  • Hyperglycemia
  • Metabolomics
  • mTOR inhibitor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Clinical Biochemistry

Cite this

Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12). / Yoshida, Kayoko; Imamura, Chiyo; Hara, Kanako; Mochizuki, Mayumi; Tanigawara, Yusuke.

In: Metabolomics, Vol. 13, No. 8, 98, 01.08.2017.

Research output: Contribution to journalArticle

Yoshida, Kayoko ; Imamura, Chiyo ; Hara, Kanako ; Mochizuki, Mayumi ; Tanigawara, Yusuke. / Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12). In: Metabolomics. 2017 ; Vol. 13, No. 8.
@article{50e5b8170eed4392bcb53460a8680523,
title = "Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)",
abstract = "Introduction: Everolimus selectively inhibits mammalian target of rapamycin complex 1 (mTORC1) and exerts an antineoplastic effect. Metabolic disturbance has emerged as a common and unique side effect of everolimus. Objectives: We used targeted metabolomic analysis to investigate the effects of everolimus on the intracellular glycometabolic pathway. Methods: Mouse skeletal muscle cells (C2C12) were exposed to everolimus for 48 h, and changes in intracellular metabolites were determined by capillary electrophoresis time-of-flight mass spectrometry. mRNA abundance, protein expression and activity were measured for enzymes involved in glycometabolism and related pathways. Results: Both extracellular and intracellular glucose levels increased with exposure to everolimus. Most intracellular glycometabolites were decreased by everolimus, including those involved in glycolysis and the pentose phosphate pathway, whereas no changes were observed in the tricarboxylic acid cycle. Everolimus suppressed mRNA expression of enzymes related to glycolysis, downstream of mTOR signaling enzymes and adenosine 5′-monophosphate protein kinases. The activity of key enzymes involved in glycolysis and the pentose phosphate pathway were decreased by everolimus. These results show that everolimus impairs glucose utilization in intracellular metabolism. Conclusions: The present metabolomic analysis indicates that everolimus impairs glucose metabolism in muscle cells by lowering the activities of glycolysis and the pentose phosphate pathway.",
keywords = "CE-TOFMS, Everolimus, Glycometabolism, Hyperglycemia, Metabolomics, mTOR inhibitor",
author = "Kayoko Yoshida and Chiyo Imamura and Kanako Hara and Mayumi Mochizuki and Yusuke Tanigawara",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s11306-017-1236-5",
language = "English",
volume = "13",
journal = "Metabolomics",
issn = "1573-3882",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)

AU - Yoshida, Kayoko

AU - Imamura, Chiyo

AU - Hara, Kanako

AU - Mochizuki, Mayumi

AU - Tanigawara, Yusuke

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Introduction: Everolimus selectively inhibits mammalian target of rapamycin complex 1 (mTORC1) and exerts an antineoplastic effect. Metabolic disturbance has emerged as a common and unique side effect of everolimus. Objectives: We used targeted metabolomic analysis to investigate the effects of everolimus on the intracellular glycometabolic pathway. Methods: Mouse skeletal muscle cells (C2C12) were exposed to everolimus for 48 h, and changes in intracellular metabolites were determined by capillary electrophoresis time-of-flight mass spectrometry. mRNA abundance, protein expression and activity were measured for enzymes involved in glycometabolism and related pathways. Results: Both extracellular and intracellular glucose levels increased with exposure to everolimus. Most intracellular glycometabolites were decreased by everolimus, including those involved in glycolysis and the pentose phosphate pathway, whereas no changes were observed in the tricarboxylic acid cycle. Everolimus suppressed mRNA expression of enzymes related to glycolysis, downstream of mTOR signaling enzymes and adenosine 5′-monophosphate protein kinases. The activity of key enzymes involved in glycolysis and the pentose phosphate pathway were decreased by everolimus. These results show that everolimus impairs glucose utilization in intracellular metabolism. Conclusions: The present metabolomic analysis indicates that everolimus impairs glucose metabolism in muscle cells by lowering the activities of glycolysis and the pentose phosphate pathway.

AB - Introduction: Everolimus selectively inhibits mammalian target of rapamycin complex 1 (mTORC1) and exerts an antineoplastic effect. Metabolic disturbance has emerged as a common and unique side effect of everolimus. Objectives: We used targeted metabolomic analysis to investigate the effects of everolimus on the intracellular glycometabolic pathway. Methods: Mouse skeletal muscle cells (C2C12) were exposed to everolimus for 48 h, and changes in intracellular metabolites were determined by capillary electrophoresis time-of-flight mass spectrometry. mRNA abundance, protein expression and activity were measured for enzymes involved in glycometabolism and related pathways. Results: Both extracellular and intracellular glucose levels increased with exposure to everolimus. Most intracellular glycometabolites were decreased by everolimus, including those involved in glycolysis and the pentose phosphate pathway, whereas no changes were observed in the tricarboxylic acid cycle. Everolimus suppressed mRNA expression of enzymes related to glycolysis, downstream of mTOR signaling enzymes and adenosine 5′-monophosphate protein kinases. The activity of key enzymes involved in glycolysis and the pentose phosphate pathway were decreased by everolimus. These results show that everolimus impairs glucose utilization in intracellular metabolism. Conclusions: The present metabolomic analysis indicates that everolimus impairs glucose metabolism in muscle cells by lowering the activities of glycolysis and the pentose phosphate pathway.

KW - CE-TOFMS

KW - Everolimus

KW - Glycometabolism

KW - Hyperglycemia

KW - Metabolomics

KW - mTOR inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85021888311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021888311&partnerID=8YFLogxK

U2 - 10.1007/s11306-017-1236-5

DO - 10.1007/s11306-017-1236-5

M3 - Article

VL - 13

JO - Metabolomics

JF - Metabolomics

SN - 1573-3882

IS - 8

M1 - 98

ER -